# Metastatic melanoma-A review of current and future perspective

**Authors:**  Qurat-ul-Ain, Muhammad Ismail  
**arXiv:** [2003.04537](https://arxiv.org/abs/2003.04537)  
**Date:** 2020-03-06  
**Summary page:** https://www.summarizepaper.com/en/paper/2003.04537v3/

## Key points

- Metastatic melanoma is a highly aggressive and treatment-resistant form of cancer
- It is the fifth most common cancer in Western countries and the most frequently diagnosed malignancy in the United States
- Despite numerous approved therapies, there has been limited success in improving survival rates for metastatic melanoma
- The etiology involves reactive oxygen species (ROS) and mutations in genes encoding receptors and protein kinases
- Surgery remains the primary treatment option due to resistance towards systemic drugs
- There is an urgent need to develop novel therapies targeting the unique molecular profile of melanoma tumors
- Qurat-ul-Ain et al. provide an overview of metastatic melanoma and discuss potential future directions for research and therapeutic development
- The authors emphasize the importance of targeting specific molecular pathways to improve treatment outcomes

## Summary

Metastatic melanoma is a highly aggressive and treatment-resistant form of cancer that poses significant challenges for patients and healthcare providers worldwide. It is the fifth most common cancer in Western countries and the most frequently diagnosed malignancy in the United States. Despite numerous systemic therapies approved by the U.S. Food and Drug Administration (FDA), including cytotoxic chemotherapy, targeted drugs, hormonal therapy, radiation therapy, bio-chemotherapy, and immunotherapies, there has been limited success in improving survival rates for metastatic melanoma. The etiology of metastatic melanoma involves not only reactive oxygen species (ROS) but also mutations in genes encoding receptors and non-receptor tyrosine/serine/threonine protein kinases. These molecular players are crucial for cell survival, growth, proliferation, migration, and signal transduction pathways. Previous studies have identified several mutated and hyperphosphorylated kinases in melanoma tumors. Surgery remains the primary treatment option due to its highly resistant nature towards systemic drugs. This resistance is compounded by the high rate of severe side effects associated with current therapies and an unsatisfactory overall response rate. Therefore, there is an urgent need to develop novel therapies that target the unique molecular profile of melanoma tumors. In a recent review titled "Metastatic Melanoma - A Review of Current and Future Perspective," Qurat-ul-Ain et al. provide an overview of the current understanding of metastatic melanoma and discuss potential future directions for research and therapeutic development. The authors highlight the importance of targeting specific molecular pathways involved in melanoma progression to improve treatment outcomes. Qurat-ul-Ain is affiliated with Dr. Panjwani Center for Molecular Medicine and Drug Research at the International Center for Chemical and Biological Sciences at the University of Karachi in Pakistan while Muhammad Ismail is also affiliated with this institution as well as the H. E. J Research Institute of Chemistry at the same university; additionally he is affiliated with Helmholtz Zentrum München's Institute of Metabolism & Cell Death in Neuherberg Germany . In conclusion, metastatic melanoma remains a significant clinical challenge due to its resistance to current systemic therapies combined with high rates of severe side effects associated with them; thus necessitating novel therapies that exploit its unique molecular profile to improve patient outcomes which was highlighted by Qurat-ul-Ain et al. 's review on "Metastatic Melanoma - A Review Of Current And Future Perspectives".